|
Lewis H. Bender joined Interleukin Genetics Inc. as CEO in January of 2008. Prior to joining Interleukin Genetics Mr. Bender was the Chief Technology Officer and CEO of Emisphere Technologies Inc. During his career Mr. Bender has been the lead negotiator for several complex business agreements that were executed including out-licensing partnerships in-licensing agreements international joint venture agreements asset acquisitions and stock purchases agreements with major pharmaceutical and biotechnology companies. The combined deals totaled over $200 million in milestone and upfront payments. He has been responsible for the management of all core product development functional areas including; discovery chemistry process chemistry analytical chemistry manufacturing pharmaceutics project management clinical research and regulatory affairs. Mr. Bender has earned both a Bachelor of Science Degree and a Master of Science degree in chemical engineering from MIT. In addition Mr. Bender also has earned an MBA from the Wharton School and a Masters of Fine Arts in International Relations at the University of Pennsylvania. | 